Embecta Corp is experiencing a significant stock decline alongside strategic moves and challenges in the MedTech sector. Learn how these factors affect investment opportunities.

Discover research on diabetic retinal disease progression from 2003 to 2022, highlighting improved management strategies and significant risk reductions.

Virginia's House Bill 1214 cuts insulin costs and enhances access for diabetics; a critical move for health insurance reform and affordability.